MEDP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
716.0M
+1.2%
707.3M
+0.1%
706.6M
-0.3%
708.5M
+7.4%
659.9M
Cost of Revenue
492.1M
-2.7%
505.7M
-0.9%
510.3M
+1.4%
503.1M
+8.7%
463.0M
Gross Profit
223.9M
+11.0%
201.6M
+2.7%
196.3M
-4.4%
205.3M
+4.3%
196.9M
Operating Expenses
58.3M
+6.4%
54.8M
-0.0%
54.8M
+5.3%
52.0M
-5.6%
55.1M
R&D
0
0
0
0
0
SG&A
51.8M
+7.6%
48.1M
+0.4%
47.9M
+6.7%
44.9M
-6.6%
48.1M
Operating Income
165.5M
+12.7%
146.8M
+3.8%
141.5M
-7.7%
153.3M
+8.1%
141.8M
EBITDA
172.1M
+12.1%
153.5M
+3.5%
148.4M
-7.5%
160.4M
+7.8%
148.9M
Net Income
137.5M
+13.3%
121.4M
-2.0%
123.9M
-8.3%
135.1M
+21.6%
111.1M
EPS (Basic)
$4.92
+14.2%
$4.31
-0.9%
$4.35
-9.0%
$4.78
+21.0%
$3.95
EPS (Diluted)
$4.84
+13.9%
$4.25
-0.7%
$4.28
-8.4%
$4.67
+21.0%
$3.86
Shares (Diluted)
28.4M
-0.6%
28.6M
-1.4%
29.0M
+0.0%
29.0M
+0.5%
28.8M
Medpace (MEDP) — Financials